Tysabri Lawsuit

Kahn Gauthier Swick is investigating possible legal actions against Biogen Idec and Elan because of two adverse events reported with the use of Tysabri (Natalizumab). Tysabri is used to treat MS (multiple sclerosis).

The Lawsuits Begin: Biogen Idec is voluntarily suspending marketing of Tysabri

The FDA approved Tysabri in November 2004 and works by reducing the frequency of exacerbations in patients with remitting-relapsing MS, which is th emost common form of Multiple Sclerosis, after one year of treatment.

Multiple Sclerosis is a disease of the brain and spinal cord caused by an unknown agent that gradually destroys the myelin covering, or sheath, of nerve fibers, resulting in a temporary interruption or disordered transmission of nerve impulses, particularly in pathways concerned with vision, sensation, and the use of limbs; disruption of impulse transmission may cause mild to moderate symptoms (numbness in the limbs to complete and permanent paralysis); onset generally occurs between ages 20 and 40, with symptoms appearing at irregular intervals for years.

If you would like more information about the Tysabri lawsuit, please call toll free 1-866-467-1400 now, or make a claim on this page.